{"id":761378,"date":"2023-06-02T07:03:27","date_gmt":"2023-06-02T11:03:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/"},"modified":"2023-06-02T07:03:27","modified_gmt":"2023-06-02T11:03:27","slug":"repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/","title":{"rendered":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights"},"content":{"rendered":"

<\/p>\n

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights<\/b><\/p>\n

Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET<\/i><\/p>\n

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE<\/a>)–
\nRepare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) synthetic lethal inhibitor in clinical development for the treatment of molecularly selected advanced solid tumors.<\/p>\n

Conference Call and Webcast Details:<\/b><\/p>\n

\nTo access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live video webcast will be available in the Investor section of the Company\u2019s website at https:\/\/ir.reparerx.com\/news-and-events\/events<\/a>. A webcast replay will also be archived for at least 30 days.<\/p>\n

About Repare Therapeutics\u2019 SNIPRx\u00ae Platform<\/b><\/p>\n

\nRepare\u2019s SNIPRx\u00ae platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company\u2019s therapies based on the genetic profile of their tumors. Repare\u2019s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx\u00ae screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.<\/p>\n

About Repare Therapeutics, Inc.<\/b><\/p>\n

\nRepare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx\u00ae platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company\u2019s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1\/2 clinical development and partnered with Roche; a preclinical Pol\u03b8 inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com<\/a>.<\/p>\n

\nSNIPRx\u00ae is a registered trademark of Repare Therapeutics Inc.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230602005075\/en\/<\/a><\/span><\/p>\n

Repare Contact:
\n<\/b>
Robin Garner
\n
Executive Director and Head of Investor Relations
\n
Repare Therapeutics Inc.
\n
investor@reparerx.com
\n<\/a><\/p>\n

Investors:
\n<\/b>
Matthew DeYoung
\n
Argot Partners
\n
repare@argotpartners.com
\n<\/a><\/p>\n

Media:
\n<\/b>
David Rosen
\n
Argot Partners
\n
david.rosen@argotpartners.com
\n<\/a>
212-600-1902<\/p>\n

KEYWORDS:<\/b> United States North America Canada Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Other Science Research Pharmaceutical Oncology General Health Health Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)– Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory … <\/p>\n

Continue reading “Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-761378","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRepare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)– Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory … Continue reading "Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-02T11:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights\",\"datePublished\":\"2023-06-02T11:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/\"},\"wordCount\":511,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/\",\"name\":\"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-06-02T11:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/","og_locale":"en_US","og_type":"article","og_title":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights - Market Newsdesk","og_description":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)– Repare Therapeutics Inc. (\u201cRepare\u201d or the \u201cCompany\u201d) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory … Continue reading \"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-02T11:03:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights","datePublished":"2023-06-02T11:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/"},"wordCount":511,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/","name":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-06-02T11:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005075r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/repare-therapeutics-to-host-conference-call-and-webcast-to-discuss-initial-rp-6306-monotherapy-data-from-phase-1-mythic-clinical-trial-and-early-combination-trials-insights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=761378"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=761378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=761378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=761378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}